
    
      This is an open-label ,single center ,non-randomized, single arm exploratory study. All
      eligible patients presented with non-keratinizing NPC and stage rT0-4N1-3M0 /rT2-4N0M0 are
      assigned to receive IMRT combined with toripalimab.
    
  